Kornimate/medical-research-clean huggingface dataset:
frozen embryo transfer in pcos patients

Conditions: Infertility

Summary: polycystic ovarian syndrome (pcos) is condition characterized by being complex, familial and polygenetic metabolic condition with heterogeneous involvement of several genes in the hypothalamic-pituitary-gonadal axis. pcos is the most incident endocrine-metabolic syndrome that is characterized by hyperandrogenemia, menstrual irregularities, and/or small cysts in one or both ovaries and could be considered as the main cause of female infertility. assisted reproductive technologies (art) were defined by the american center for disease control as any fertility-related treatments where eggs or embryos are manipulated. in vitro fertilization involves the transfer of fresh embryos, however, the freeze-all strategy that entails cryopreservation of all embryos to be transferred subsequently in un-stimulated cycle to guard against the negative effects of controlled ovarian stimulation on the endometrium and to minimize the risk of ovarian hyper-stimulation syndrome. intracytroplasmatic sperm injection (icsi) is a common procedure used to improve reproductive results, even among couples without male factor infertility. however, there are several points of controversy in the fields of art traditionally, multiple embryo transfer strategy was used to increase the chance for getting a baby, however, multiple pregnancy is a common complication for this strategy with subsequent adverse fetal, maternal and neonatal outcomes. also, the developmental stage of embryos at time of transfer; cleavage versus blastocyst was a matter of debit, but giving the chance for in-vitro maturation to the stage of blastocyst increased the possibility of getting good quality embryo to be transferred. however, the exaggeration of prolongation of the in-vitro duration appeared as a trend, but recent studies found no advantages for transfer of d7 or d6 blastocyst over d5 blastocyst transfer (bt).


Eligibility criteria:
inclusion criteria: * infertile women fulfilling at least two of the rotterdam criteria for diagnosis of pcos; * aged 20-35 years; * had body mass index (bmi) of less than 35 kg/m2; * mild hirsutism on ferriman-gallwey (fg) visual scoring system; * their hormonal profile of serum amh \>4.5, fsh \ 5.39; * had no previous attempts of icsi were included in the study. exclusion criteria: * patients who were out of the predetermined age range and bmi; * had uterine abnormalities; * hydrosaplnix; * recurrent miscarriage; * medical diseases interfering with or being complicated by occurrence of pregnancy; * cases requiring icsi with tese samples; * had obesity-inducing endocrinopathy * severe symptomatizing hypovitaminosis or maintained on hormonal contraception within the last 6 months before inclusion in the study, were excluded from the study.
early directed physical therapy in the management of mechanically ventilated patients in a medical intensive care unit

Conditions: Mechanically Ventilated Patients

Summary: to study all icu patients with an independent baseline functional status, who experience a critical illness requiring intubation and mechanical ventilation, evaluating the role of protocol-directed, early physical and occupational therapy on the incidence of critical illness associated functional debilitation. our goal is to hasten the recovery of independent physical functioning as well as to reduce icu delirium in the group of patients who begin this intervention from the earliest hours of ventilator dependence.


Eligibility criteria:
inclusion criteria 1. patients intubated and mechanical ventilated for \< 72 hours 2. age \> 18 years 3. baseline independent functional status as assessed by a barthel index score \> 70 collected from a proxy reflecting baseline health 2 weeks prior to critical illness exclusion criteria 1. rapidly evolving neurological/neuromuscular disease 2. cardiac arrest 3. irreversible conditions with six month mortality estimated at \> 50% 4. elevated intracranial pressure 5. multiple absent limbs (precluding complete musculoskeletal examination) 6. enrollment in another trial

Keywords: mechanical ventilation physical therapy occupational therapy mobilization clinical protocols icu acquired weakness critical illness myopathy muscle atrophy intensive care unit randomized controlled trial
effects of repetitive transcranial magnetic stimulation (rtms) on cannabis use and cognitive outcomes in schizophrenia

Conditions: Repetitive Transcranial Magnetic Stimulation (rTMS); Schizophrenia; Cannabis Use Disorder; Cognition

Summary: the high prevalence of cannabis and other substance use disorders are a major barrier to recovery in people with schizophrenia. moreover, schizophrenia patients have significant deficits in cognitive function, which may be exacerbated by cannabis use. complicating these problems is the lack of evidence-based treatments for co-morbid cannabis use disorders (cuds) in schizophrenia; there are no established pharmacotherapies. therefore, this study is investigating the effects of high-frequency (20hz) repetitive transcranial magnetic stimulation (rtms) on cannabis use disorder and cognitive function in patients with co-morbid schizophrenia/schizoaffective disorder. the proposed study would be the first randomized, double-blind, sham controlled trial of rtms in patients with schizophrenia and co-morbid cud. a total of n=40 schizophrenia smokers with co-morbid cannabis use disorder will be assigned to either active rtms (n=20) or sham rtms (n=20) as a treatment regimen of 5x/week treatment for four consecutive weeks. all participants will receive weekly behavioral therapy for 4 weeks. the investigators predict that active rtms will be well-tolerated and superior to sham rtms for the treatment of cud in schizophrenia.


Eligibility criteria:
inclusion criteria: 1. male (80%) or female (20%); 2. age 18-55; 3. meet the diagnostic and statistical manual of mental disorders version 5 (dsm-5) criteria for schizophrenia (sz) or schizoaffective disorder and cannabis use disorder with physiological dependence; 4. full scale intelligence quotient (iq) ≥ 80 determined through the wechsler test of adult reading (wtar); 5. non-smokers or cigarette smokers as confirmed with fragerstrom test for nicotine dependence (ftnd) score of 5 or higher, self reported smoking of at lest 5 cigarettes per day (measured by the timeline follow back), and verified by a smokerlyzer test, cut-off as 10 ppm. exclusion criteria: 1. dsm-5 diagnoses of alcohol, substance or polyuse substance use disorder in the past 6 months (other than cannabis/caffeine or nicotine); 2. currently active suicidal ideation or self-harm (suicidal or non-suicidal) as assessed by the structured clinical interview for dsm-5 (scid-5); 3. head injury resulting in loss of consciousness (\>5 minutes) and hospitalization; 4. major neurological or medical illness including seizure disorder or syncope; 5. metallic implants; 6. history of rtms treatment; 7. pregnancy.

Keywords: sham repetitive transcranial magnetic stimulation (rtms) schizophrenia cannabis use disorder cognitive function
clinical and molecular aspects of early osteoarthritis

Conditions: Early Osteoarthritis

Summary: the etiology of osteoarthritis is varied, ranging from multifactorial, environmental to monogenic. in individuals in whom osteoarthritis appears earlier than in the general population, it is called early osteoarthritis. to our knowledge, there are no large-scale genetic studies on people with early osteoarthritis. the investigators therefore sought to study the causes of monogenic osteoarthritis in people suffering from early non-syndromic osteoarthritis. material and method from 2013 to 2019, experts in constitutional bone disease sent patients with non-syndromic early osteoarthritis for genetic analysis to our center of competence for constitutional bone diseases. the sequencing of a panel of genes was carried out by ngs.


Eligibility criteria:
inclusion criteria: - patients with early osteoarthritis who have undergone genetic sequencing exclusion criteria: - patients refusing to participate in research

Keywords: genetic sequencing
dapsone gel 5% and tazarotene cream 0.1% versus tazarotene cream 0.1% monotherapy for facial acne vulgaris

Conditions: Acne Vulgaris

Summary: a 12-week evaluation of the safety and efficacy of dapsone gel 5% when used with tazarotene cream 0.1% compared with tazarotene cream 0.1% monotherapy in treating moderate to severe facial acne vulgaris


Eligibility criteria:
inclusion criteria: * facial acne vulgaris characterized by the following: 30-100 facial inflammatory lesions; and 25-100 facial non-inflammatory lesions; stable disease, non-rapidly regressing facial acne vulgaris; and, 3 or more nodules and/or cysts (diameter of 1cm or greater). female subjects of childbearing potential must have a negative pregnancy test at baseline and practice reliable method of contraception throughout the study exclusion criteria: * non-compliance with washout period; history of clinically significant anemia or hemolysis; skin disease/disorder that might interfere with diagnosis or evaluation of acne vulgaris; allergy or sensitivity to any component of the test medications
alcohol pharmacotherapy for hiv+ prisoners

Conditions: Alcohol Dependence; Problem Drinking; Hazardous Drinking; Human Immunodeficiency Virus; AIDS

Summary: this is a randomized controlled trial of injectable intramuscular naltrexone (xr-ntx) versus intramuscular placebo among hiv-infected prisoners meeting diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv) criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. we hypothesize that extended release naltrexone (xr-ntx) will result in improved hiv outcomes (lower log10 hiv-1rna levels and higher cd4 count) as well as improved alcohol treatment outcomes, and reduced drug/sex hiv related risk behaviors and decreased rates of reincarceration.

inspire is a randomized controlled trial of injectable intramuscular ntx (xr-ntx) versus intramuscular placebo among human immunodeficiency (hiv) infected prisoners meeting dsm-iv criteria for alcohol dependence or problem drinking, who are transitioning to the community and seeking treatment to prevent relapse to alcohol use. while the combine trial has demonstrated the effectiveness of oral naltrexone in a group of active alcohol dependent persons in decreasing relapse to alcohol use over placebo, naltrexone has not been studied in people who have a history of current alcohol dependence prior to incarceration, are incarcerated and not actively using alcohol and are likely to return to alcohol use when released. in this study, we conduct a placebo-controlled trial to determine if naltrexone has an effect in this group, which could be important in making the case for having naltrexone available to alcohol dependent or problem drinking hiv+ prisoners prior to release. we will compare their hiv treatment (hiv-1 rna levels, cd4 count), alcohol treatment (time to relapse to heavy drinking, percent of days drinking, percent of days abstinent and alcohol craving) and hiv risk behavior (sexual and drug-related risks) outcomes. the hypotheses include: i. xr-ntx will result in improved hiv clinical outcomes, including changes in hiv-1 rna levels, and higher cd4 counts. ii. xr-ntx will result in improved alcohol treatment outcomes, including longer time to alcohol relapse, lower percent days drinking, and lower craving for alcohol.

Eligibility criteria:
inclusion criteria: 1. hiv+ 2. inmates returning to new haven or hartford 3. meets criteria for alcohol dependence (using diagnostic and statistical manual iv) or problem drinking (using alcohol use disorder identification test-audit) 4. gives informed consent 5. english or spanish speaker 6. \> 18 yrs exclusion criteria: 1. on opiate pain medication or expressing need for them 2. aspartate aminotransferase (ast) and alanine aminotransferase (alt) \> 5x the upper limit of normal 3. evidence of child's pugh class c cirrhosis 4. pending felony charges 5. pregnant or unwilling to take contraceptive measures 6. subject is part of another pharmacological research study

Keywords: hiv acquired immunodeficiency syndrome alcohol dependence cd4 hiv-1 rna alcohol treatment outcomes
understanding male breast cancer: salah azaïz cancer institute experience

Conditions: Male Breast Cancer

Summary: the goal of this study is to evaluate the salah azaïz cancer institute male breast cancer patients population over a period of 14 years. goal of the retrospective part: to gather clinicopathologic data and follow-up outcomes of male breast cancer patients diagnosed and/or treated at salah azaïz cancer institute from 2004 to 2013. goal of the prospective part: to create a registry of male patients with breast cancer for a period of 48 months (from 2014 to 2017).


Eligibility criteria:
inclusion criteria: histological diagnosis of male breast cancer

Keywords: breast cancer male
effect of antiviral therapy on hvpg in patients with viral cirrhosis

Conditions: Portal Hypertension

Summary: complications associated with portal hypertension are the leading cause of death in patients with cirrhosis. until now, hepatic venous pressure gradient (hvpg) - the difference between the wedged hepatic venous pressure (whvp) and the free hepatic vein pressure (fhvp)- has been the criterion standard to determine portal pressure. antiviral therapy may decrease hvpg which needs to be verified.


Eligibility criteria:
inclusion criteria: * patients with viral cirrhosis were diagnosed; * age 18-80 years; * need and willing to accept measure hvpg; * first hvpg measurement of more than 5 mmhg; * signed informed consent exclusion criteria: * patients with viral cirrhosis have been treated with antiviral therapy and have achieved virological response; * ready to accept or have accepted a tips procedure; * splenic embolization was performed; * inaccurate measurement of hvpg due to combined hepatic venous shunt; * complicated with alcoholic liver disease, autoimmune liver disease or other types of liver disease; * complicated with liver cancer or other organ malignancy; * combined with severe cardiopulmonary disease affects survival; * complicated with severe renal insufficiency; * concomitant portal vein cavernous degeneration or extensive portal vein thrombosis; * women who are planning to become pregnant or who are pregnant or breastfeeding.
efficacy evaluation of systane® ultra in patients scheduled for cataract surgery

Conditions: Dry Eye; Cataract Surgery

Summary: the purpose of this study is to evaluate the effectiveness of fid 112903 (systane ultra® lubricating drops) plus standard of care to standard of care alone, in subjects with a history of intermittent eye irritation or dryness related to environmental factors and scheduled for routine cataract surgery.


Eligibility criteria:
inclusion criteria: * patients must be at least 18 years of age * patients must be seeking routine cataract extraction with monofocal intraocular lens implantation exclusion criteria: * patients for whom both eyes do not meet all inclusion criteria and either eye meets any exclusion criteria. * patients cannot have a history of hypersensitivity to any component of fid 112903. * patients cannot have previous intraocular or corneal surgery or any planned within 30 days. * patients cannot use any ocular medications other than test article and standard of care post-op medications in past 14 days or during study. * patients cannot be on chronic systemic corticosteroid or other immunosuppressive therapy. * patients cannot have a history of steroid-responsive rise in intraocular pressure, glaucoma, or preoperative intraocular pressure \>25 millimeters mercury in either eye. * patients cannot have a history and/or current evidence of the following: clinically significant corneal scarring, blepharitis or macular pathology in either eye, herpes zoster or herpes simplex keratitis.
study of combined rhumab vegf and capecitabine-based chemoradiation for patients with locally advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the goal of this clinical research study is to find the highest safe dose of the drug bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. the effect that this combination treatment has on the tumor will also be studied.

this study administers 50.4 gy of radiation for unresectable pancreatic cancer with concurrent capecitabine and an experimental drug, bevacizumab. the drug is an antiangiogenic agent (kills tumor blood vessels) and has been shown in preclinical models to enhance the antitumor effect of radiation and chemotherapy.

Eligibility criteria:
inclusion criteria: * cytology or histologic proof of adenocarcinoma of the pancreatic head, body or tail prior to treatment. * patients with nonmetastatic, unresectable, disease are eligible. * patients with regional nodal disease are eligible. * karnofsky performance status \>/=70. * no upper age restriction. * absolute granulocyte count \>1,500 cells/mm3 and platelet count at least 100,000 cells/mm3. * serum bilirubin less than 5mg/dl prior to the start of therapy with adequate biliary decompression. * adequate bilateral renal function. * serum creatinine \<1.5 mg/dl. * adequate liver function; alanine aminotransferase (alt)/aspartate aminotransferase (ast)\</=5 times upper limit of normal. * sexually active men must practice contraception during study. * patients must sign study-specific consent form. exclusion criteria: * history or evidence upon physical examination of cns disease. * active infection requiring parenteral antibiotics on day 0. major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipation of need for major surgical procedure during the course of the study. * current or recent use of full-dose oral or parenteral anticoagulants or thrombolytic agent. * chronic, daily treatment with aspirin or nonsteroidal anti-inflammatory medications. * pregnancy or lactation. * proteinuria at baseline or impairment of renal function. * serious, nonhealing wound, ulcer, or bone fracture. * evidence of bleeding diathesis or coagulopathy * clinically significant cardiovascular disease, congestive heart failure, serous cardiac arrhythmia requiring medication, or significant peripheral vascular disease within 1 year prior to day 0. * history of aneurysms, strokes, transient ischemic attacks, and arteriovenous malformations. * serous concomitant medical or psychiatric disorders. * cohort receiving capecitabine

Keywords: pancreatic cancer pancreas cancer pancreas
epidemiological, clinical, microbiological and outcome description of patients with klebsiella sp meningitis

Conditions: Meningitis

Summary: klebsiella pneumoniae is implicated in the occurrence of severe pneumonia. most klebsiella pneumoniae infections are associated with care and occur in patients with compromised immune defenses. more recently, cases of hepatic abscess and acute community meningitis related to strains of klebsiella pneumoniae have been reported. the mortality of these infections is important, most often due to a delayed diagnosis. the poor prognostic factors reported in the literature for very low numbers are: advanced age, coma, septic shock, glyceryachia \ 750 mg / dl. in addition, no study has specifically focused on the factors of occurrence and factors associated with klebsiella sp. indeed, meningitis related to klebsiella pneumoniae seems to be a rare but probably underestimated event whose risk factors, clinical presentation, microbiological are little known and the treatment modalities of this severe infection are not codified.


Eligibility criteria:
inclusion criteria: * man or woman whose age ≥ 18 years * patient with meningitis klebsiella sp., hospitalized in one of the hospitals of the clinical microbiology group * francophone patient exclusion criteria: * patient under tutorship or curatorship * patient deprived of liberty * patient under safeguard of justice * patient opposing his participation
the effect of square stepping exercise training on cognitive functions and quality of life in geriatric individuals

Conditions: Healthy

Summary: this study was designed to investigate the effects of square-stepping exercise training on cognitive functions and quality of life in geriatric individuals. the volunteer participants in the study were randomly divided into two groups: a square-stepping exercise group and a control group. in the study, participants in the exercise training groups received square stepping exercises three days a week for six weeks, while those in the control group did not undergo any training. both groups were assessed before and six weeks after the training period. the investigators used several assessment tools including hodkinson's mental test, montreal cognitive assessment, stroop test, trail making test, and the turkish world health organization quality-of-life scale.


Eligibility criteria:
inclusion criteria: * individuals aged between 65-75 years old, * able to walk independently, * hodkinson mental test score ≥ 8, * without any neurological or lower extremity-affecting diseases, * healthy geriatric individuals who agreed to participate in the study were included. exclusion criteria: * using 3 or more medications, * hodkinson mental test score \<8, * currently participating in any exercise/rehabilitation program, * geriatric individuals with a history of lower extremity surgery

Keywords: geriatric cognitive functions square stepping exercise quality of life
demonstrate exubera works as well as avandia when added to sulfonylurea + metformin in controlling glucose

Conditions: Diabetes Mellitus

Summary: * whether a combination of three therapies - metformin and a sulfonylurea plus exubera, an investigational drug, controls your diabetes at least as much as a triple combination therapy of metformin and a sulfonylurea plus avandia, a food and drug administration (fda) approved drug. * whether a combination of two therapies - metformin plus exubera controls your diabetes at least as much as a as a triple combination therapy of metformin and a sulfonylurea plus avandia.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * currently treated and on a stable doses of drugs for the preceding two (2) months exclusion criteria: * type 1 diabetes * smoking